IMUX is trading 5% up today at $15.61 despite a lack of fresh company-specific catalysts, notably outperforming broadly weaker U.S. indices.
- There are no new earnings releases, FDA decisions, or major analyst calls tied directly to Immunic today.
- The uptick appears to be driven by idiosyncratic buying or technical trading flows rather than fundamental news developments.